Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).

Fragment screening of a thermostabilized mGlu5 receptor using a high-concentration radioligand binding assay enabled the identification of moderate affinity, high ligand efficiency (LE) pyrimidine hit 5. Subsequent optimization using structure-based drug discovery methods led to the selection of 25, HTL14242, as an advanced lead compound for further development. Structures of the stabilized mGlu5 receptor complexed with 25 and another molecule in the series, 14, were determined at resolutions of 2.6 and 3.1 Å, respectively.

[1]  S. Nakanishi.  Molecular diversity of glutamate receptors and implications for brain function. , 1992, Science.

[2]  A. Ritzén,et al.  Efficacy switching SAR of mGluR5 allosteric modulators: highly potent positive and negative modulators from one chemotype. , 2011, Bioorganic & medicinal chemistry letters.

[3]  Ilya Pyatkin,et al.  Positive and negative modulation of group I metabotropic glutamate receptors. , 2008, Journal of medicinal chemistry.

[4]  Daniela Berg,et al.  Treatment of Levodopa-Induced Dyskinesias : Results of 2 Randomized Controlled Trials , 2011 .

[5]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[6]  P Jeffrey Conn,et al.  A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. , 2003, Molecular pharmacology.

[7]  Diane Joseph-McCarthy,et al.  Fragment-Based Lead Discovery and Design , 2014, J. Chem. Inf. Model..

[8]  R. Reilmann,et al.  A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[9]  V. Cherezov,et al.  Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.

[10]  Andrew S. Felts,et al.  Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. , 2013, Bioorganic & medicinal chemistry letters.

[11]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[12]  G. Rastelli,et al.  Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity. , 2015, Bioorganic & medicinal chemistry.

[13]  R. Walmsley,et al.  The GADD45a-GFP GreenScreen HC assay. , 2012, Methods in molecular biology.

[14]  Jens Meiler,et al.  Discovery of 2‐(2‐Benzoxazoyl amino)‐4‐Aryl‐5‐Cyanopyrimidine as Negative Allosteric Modulators (NAMs) of Metabotropic Glutamate Receptor 5 (mGlu5): From an Artificial Neural Network Virtual Screen to an In Vivo Tool Compound , 2012, ChemMedChem.

[15]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[16]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[17]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[18]  J. Wettstein,et al.  Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. , 2015, Current opinion in pharmacology.

[19]  J. Brennan,et al.  Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression , 2013, Neuropharmacology.

[20]  Z. Rankovic,et al.  CNS drug design: balancing physicochemical properties for optimal brain exposure. , 2015, Journal of medicinal chemistry.

[21]  Dahlia R. Weiss,et al.  Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. , 2015, Current opinion in pharmacology.

[22]  P Jeffrey Conn,et al.  "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. , 2011, Biochemistry.

[23]  W. Spooren,et al.  Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. , 2000, The Journal of pharmacology and experimental therapeutics.

[24]  F. Gasparini,et al.  AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. , 2014, Bioorganic & medicinal chemistry.

[25]  Christopher G. Tate,et al.  Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design , 2013, Journal of medicinal chemistry.

[26]  P. Goadsby,et al.  Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? , 2010, Expert opinion on investigational drugs.

[27]  K. A. Emmitte,et al.  Recent advances in the design and development of novel negative allosteric modulators of mGlu(5). , 2011, ACS chemical neuroscience.

[28]  Nathan Robertson,et al.  The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery , 2011, Neuropharmacology.

[29]  György G Ferenczy,et al.  How are fragments optimized? A retrospective analysis of 145 fragment optimizations. , 2013, Journal of medicinal chemistry.

[30]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[31]  M. Grenon,et al.  Discovery and structure-activity relationship of 1,3-cyclohexyl amide derivatives as novel mGluR5 negative allosteric modulators. , 2013, Bioorganic & medicinal chemistry letters.

[32]  P. Raboisson,et al.  Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. , 2012, Bioorganic & medicinal chemistry letters.

[33]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[34]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[35]  S. Gatti,et al.  Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 – present) , 2015, Expert opinion on therapeutic patents.

[36]  C. Lindsley,et al.  Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. , 2011, Bioorganic & medicinal chemistry letters.

[37]  J. Pecknold,et al.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. , 1982, Journal of clinical psychopharmacology.

[38]  K. Huizar,et al.  Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers , 2013, European journal of pain.

[39]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[40]  R. Shigemoto,et al.  Chapter III Metabotropic glutamate receptors — immunocytochemical and in situ hybridization analyses , 2000 .

[41]  Jeffrey B. Sperry,et al.  A Robust Process for an mGluR5 Negative Allosteric Modulator: Difluoromethylation and Sonogashira Coupling on Large Scale , 2012 .

[42]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[43]  P. Fontoura,et al.  P.2.f.027 The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomised, double-blind, placebo-controlled study , 2014, European Neuropsychopharmacology.

[44]  J. Cianfrogna,et al.  Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. , 2014, Journal of medicinal chemistry.

[45]  K. Gregory,et al.  A Novel Metabotropic Glutamate Receptor 5 Positive Allosteric Modulator Acts at a Unique Site and Confers Stimulus Bias to mGlu5 Signaling , 2013, Molecular Pharmacology.

[46]  Yue-Zhong Shu,et al.  Identification of Glutathione Conjugates of Acetylene-Containing Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 , 2015, Drug Metabolism and Disposition.

[47]  P. Zwart,et al.  Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.

[48]  K. Emmitte.  mGlu5 negative allosteric modulators: a patent review (2010 – 2012) , 2013, Expert opinion on therapeutic patents.

[49]  Fabrizio Gasparini,et al.  [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. , 2002, Bioorganic & medicinal chemistry letters.

[50]  C. Lindsley,et al.  Synthesis, SAR and Unanticipated Pharmacological Profiles of Analogues of the mGluR5 Ago‐potentiator ADX‐47273 , 2009, ChemMedChem.

[51]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[52]  A. Doré,et al.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.

[53]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[54]  P. Malfertheiner,et al.  Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro‐oesophageal reflux disease , 2011, Alimentary pharmacology & therapeutics.

[55]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[56]  Stephen R. Morairty,et al.  Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[57]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.